PL2268635T3 - Związki heterocykliczne - Google Patents

Związki heterocykliczne

Info

Publication number
PL2268635T3
PL2268635T3 PL08874003T PL08874003T PL2268635T3 PL 2268635 T3 PL2268635 T3 PL 2268635T3 PL 08874003 T PL08874003 T PL 08874003T PL 08874003 T PL08874003 T PL 08874003T PL 2268635 T3 PL2268635 T3 PL 2268635T3
Authority
PL
Poland
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
PL08874003T
Other languages
English (en)
Inventor
Chi-Feng Yen
Cheng-Kung Hu
Chang-Pin Huang
Ying-Huey Huang
Gholam Hossein Hakimelahi
Chi-Hsin Richard King
Original Assignee
Taigen Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taigen Biotechnology Co Ltd filed Critical Taigen Biotechnology Co Ltd
Publication of PL2268635T3 publication Critical patent/PL2268635T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08874003T 2008-04-21 2008-11-03 Związki heterocykliczne PL2268635T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4649608P 2008-04-21 2008-04-21
EP08874003.0A EP2268635B1 (en) 2008-04-21 2008-11-03 Heterocyclic compounds
PCT/US2008/082202 WO2009131598A1 (en) 2008-04-21 2008-11-03 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
PL2268635T3 true PL2268635T3 (pl) 2015-11-30

Family

ID=41201620

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08874003T PL2268635T3 (pl) 2008-04-21 2008-11-03 Związki heterocykliczne

Country Status (21)

Country Link
US (1) US8372849B2 (pl)
EP (1) EP2268635B1 (pl)
JP (1) JP5661607B2 (pl)
KR (1) KR101579999B1 (pl)
CN (1) CN101565404B (pl)
AU (1) AU2008355098B2 (pl)
CA (1) CA2720229C (pl)
CY (1) CY1116802T1 (pl)
DK (1) DK2268635T3 (pl)
EA (1) EA019289B1 (pl)
ES (1) ES2545731T3 (pl)
HK (1) HK1138269A1 (pl)
HR (1) HRP20150932T2 (pl)
HU (1) HUE025179T2 (pl)
NZ (1) NZ588989A (pl)
PL (1) PL2268635T3 (pl)
PT (1) PT2268635E (pl)
SI (1) SI2268635T1 (pl)
TW (1) TWI444188B (pl)
WO (1) WO2009131598A1 (pl)
ZA (1) ZA201008262B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201021855A (en) * 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
CN103204816B (zh) * 2012-01-16 2016-04-27 中国人民解放军军事医学科学院毒物药物研究所 哌嗪基嘧啶类衍生物及其制备方法和用途
ES2681050T3 (es) * 2012-04-11 2018-09-11 Acerta Pharma B.V. Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética
RU2704008C2 (ru) 2014-09-22 2019-10-23 Нэшнл Хелс Ресерч Инститьютс Гетероциклические соединения и их применение
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
CA3047146C (en) * 2017-01-10 2021-08-31 Kak-Shan Shia Heterocyclic compounds and use thereof
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CN108794414B (zh) * 2018-06-22 2021-01-01 浙江大学 芳酰胺基取代的均三嗪类化合物及制备和应用
CN116120195A (zh) * 2022-12-29 2023-05-16 长兴宜生药物科技有限公司 一种催化制备培哚普利中间体的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6029A (en) * 1849-01-16 Method of directing the scoops in dredging machines
US3007A (en) * 1843-03-21 Improvement in salt-boilers
US5034560A (en) 1990-10-19 1991-07-23 The Standard Oil Company Synthesis of ethylamines
WO1993001498A1 (en) 1991-07-04 1993-01-21 Immunodex K/S Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
WO1997020823A2 (en) 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
AU3295297A (en) 1996-06-04 1998-01-05 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
WO1998024782A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
CA2333927A1 (en) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
BR9913374A (pt) 1998-08-20 2001-05-15 Agouron Pharmaceticals Inc Compostos de gnrh não peptìdicos, composição farmacêutica e métodos para regular a secreção de gonadotropinas em mamìferos
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
TW550258B (en) 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
WO2001047921A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
EP1345927B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
WO2004067516A1 (en) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
BRPI0414630A (pt) 2003-09-22 2006-11-07 Hoffmann La Roche derivados ciclohexìlicos substituìdos com aminoalquilamida
EP1735319B1 (en) * 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
KR101347830B1 (ko) 2004-05-23 2014-01-07 에이치엠아이, 인코포레이티드 테라뮤틴 조절물질
JP2006124387A (ja) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
AU2006259525B2 (en) * 2005-06-14 2012-05-24 Gpcr Therapeutics, Inc Pyrimidine compounds
JP2009506125A (ja) 2005-08-29 2009-02-12 ジェラルド・エム・ハウシー セラミューテイン・モジュレーター
BRPI0616575A2 (pt) 2005-09-27 2011-06-21 Irm Llc compostos e composições contendo diarilamina, seu uso como moduladores de receptores de c-kit bem como método para sua produção
AU2006318383A1 (en) 2005-11-23 2007-05-31 Gerard M. Housey Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
RU2008140382A (ru) 2006-03-16 2010-04-27 Новартис АГ (CH) Гетероциклические органические соединения, например, для лечения меланомы
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators

Also Published As

Publication number Publication date
CY1116802T1 (el) 2017-03-15
EA019289B1 (ru) 2014-02-28
KR20110008085A (ko) 2011-01-25
AU2008355098A1 (en) 2009-10-29
CA2720229A1 (en) 2009-10-29
WO2009131598A1 (en) 2009-10-29
TWI444188B (zh) 2014-07-11
US20090264339A1 (en) 2009-10-22
CN101565404B (zh) 2012-12-05
EP2268635B1 (en) 2015-06-10
HK1138269A1 (en) 2010-08-20
CA2720229C (en) 2015-02-17
US8372849B2 (en) 2013-02-12
NZ588989A (en) 2012-03-30
SI2268635T1 (sl) 2015-10-30
HRP20150932T2 (hr) 2017-10-20
DK2268635T3 (en) 2015-09-14
ES2545731T3 (es) 2015-09-15
ZA201008262B (en) 2011-07-27
JP5661607B2 (ja) 2015-01-28
PT2268635E (pt) 2015-10-06
AU2008355098B2 (en) 2012-11-15
TW200944206A (en) 2009-11-01
JP2011519360A (ja) 2011-07-07
HRP20150932T1 (en) 2015-10-09
HUE025179T2 (en) 2016-02-29
EA201071221A1 (ru) 2011-08-30
EP2268635A4 (en) 2012-02-22
KR101579999B1 (ko) 2015-12-23
EP2268635A1 (en) 2011-01-05
CN101565404A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
GEP20135844B (en) Heterocyclic compound
EP2269990A4 (en) HETEROCYCLIC COMPOUND
IL212186A0 (en) Fungicidal heterocyclic compounds
GB0800035D0 (en) Compounds
EP2202223A4 (en) HETEROCYCLIC COMPOUND
HK1148283A1 (en) Heterocyclic derivatives
IL231955B (en) Tetracycline compounds are substituted at the 7c position with fluorine
AP2010005364A0 (en) Novel heterocyclic compounds.
EP2210876A4 (en) HETEROCYCLIC CONNECTION
EP2295406A4 (en) HETEROCYCLIC CONNECTION
HRP20150932T1 (en) Heterocyclic compounds
GB0800367D0 (en) Compounds
GB0921210D0 (en) Novel heterocyclic derivatives
GB0801220D0 (en) Compounds
GB0801265D0 (en) Compounds
GB0919817D0 (en) Heterocyclic compounds
GB0919816D0 (en) Heterocyclic compounds
IL210015A0 (en) Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
EP2299809A4 (en) SUBSTITUTED CYCLOHEXYLIDES-ETHYLIDES-OCTAHYDROINDENE COMPOUNDS
GB0802192D0 (en) Compounds
GB0802587D0 (en) Compounds
GB0802586D0 (en) Compounds
GB0801219D0 (en) Compounds
GB0800961D0 (en) Compounds
GB0801596D0 (en) Compounds